Compare Johnson & Johnson (JNJ) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Otis Worldwide Corp — how do they compare? Johnson & Johnson trades at $260.72 (market cap $618.09B), while Otis Worldwide Corp trades at $66.56 (market cap $25.17B). The key difference: Johnson & Johnson is far larger — about 24.6× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Otis Worldwide Corp for 66 Days on average.
| JNJ | OTIS | |
|---|---|---|
Market Cap | $618.09B | $25.17B |
Volume | 6,050,983 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $278.43 | $93.62 |
52-Week Low | $186.00 | $64.05 |
Typical Hold Time | 129 Days | 66 Days |
Enterprise Value | $646.37B | $33.20B |
Dividend Yield | 2.09% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Otis Worldwide trades at $66.14, up 0.61% today but near its 52-week low, with technical indicators showing bearish momentum. The company reported mixed Q2 2026 results, missing EPS estimates while maintaining strong service revenue growth. Recent CEO succession news and China market challenges create uncertainty, though analyst consensus remains positive with a $87 price target representing 31% upside potential.
The stock presents a value opportunity with reasonable P/E of 16.99 and P/S of 1.73, but faces margin pressure and execution risks. Service segment growth and modernization backlog provide stability, while weak equipment demand and China exposure remain headwinds. Institutional ownership shows mixed signals with recent buying and selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
